BIVV003
Total Payments
$80,842
Transactions
22
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $80,842 | 22 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $80,842 | 22 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease (PRECIZN-1) | BIOVERATIV THERAPEUTICS INC. | $43,849 | 0 |
| A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adult | BIOVERATIV THERAPEUTICS INC. | $36,993 | 0 |
Top Doctors Receiving Payments for BIVV003
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Detroit, MI | $80,842 | 22 |
Ad
Manufacturing Companies
- BIOVERATIV THERAPEUTICS INC. $80,842
Product Information
- Type Drug
- Total Payments $80,842
- Total Doctors 0
- Transactions 22
About BIVV003
BIVV003 is a drug associated with $80,842 in payments to 0 healthcare providers, recorded across 22 transactions in the CMS Open Payments database. The primary manufacturer is BIOVERATIV THERAPEUTICS INC..
Payment data is available from 2019 to 2019. In 2019, $80,842 was paid across 22 transactions to 0 doctors.
The most common payment nature for BIVV003 is "Unspecified" ($80,842, 100.0% of total).
BIVV003 is associated with 2 research studies, including "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease (PRECIZN-1)" ($43,849).